Search

Displaying results 2801 - 2810 of 10000 in total
  1. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    [A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.

  2. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription.

    Products: Evrysdi Powder for oral solution 0.75 mg/mL, EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/ML
  3. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    It also inhibits prostaglandin biosynthesis.

    Synonyms: N-(2,6-dichloro-m-tolyl)anthranilic acid, N-(2,6-dichloro-3-methylphenyl)anthranilic acid
  4. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. … Bufexamac was also withdrawn by the EMA in April 2010.

    Synonyms: 4-Butoxy-N-hydroxybenzeneacetamide
  5. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. … Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. … The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

  7. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin

  8. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. … Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

  9. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. … [T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]

  10. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.